[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355629-105":59,"doc-detail-355629-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tgf-inhibitor-potentiates-osimertinib-induced-anti-tumor-immunity-in-egfr-mutant-lung-cancer","TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer","","Immunotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) remains difficult because EGFR tyrosine kinase inhibition can induce both antitumor immunity and immunosuppressive cytokines such as transforming growth factor-β (TGF-β). A syngeneic mouse model evaluated whether TGF-β inhibition strengthens osimertinib-driven antitumor immunity using osimertinib with nintedanib or vactosertib. Tumor microenvironment changes were assessed by immunohistochemistry, western blot, and flow cytometry. Osimertinib upregulated TGF-β, and the combination with nintedanib significantly enhanced in vivo antitumor effects while increasing effector T cells and Granzyme B+ areas and reducing CD206+ cells, TGF-β, and SMAD2/3 expression. Similar results occurred with vactosertib, supporting a novel therapeutic approach.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tgf-inhibitor-potentiates-osimertinib-induced-anti-tumor-immunity-in-egfr-mutant-lung-cancer/355629/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tgf-inhibitor-potentiates-osimertinib-induced-anti-tumor-immunity-in-egfr-mutant-lung-cancer/355629.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is immunotherapy challenging in EGFR-mutated NSCLC?","Question",{"text":113,"@type":114},"Clinical trials show limited efficacy of immune checkpoint inhibitors in EGFR-mutant NSCLCs, likely due to low immunogenicity and an immunosuppressive tumor microenvironment driven by oncogenic EGFR signaling.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What did the study test to potentiate osimertinib-induced immunity?",{"text":118,"@type":114},"The study evaluated whether TGF-β inhibition potentiates osimertinib-induced antitumor immunity by combining osimertinib with nintedanib or vactosertib and assessing changes in the tumor microenvironment.",{"name":120,"@type":111,"acceptedAnswer":121},"What immune and molecular changes were observed with the combination therapy?",{"text":122,"@type":114},"Combination therapy increased effector T cells (CD8+CD44+CD62L−) and Granzyme B+ areas while decreasing CD206+ cells, along with reduced TGF-β and SMAD2/3 expression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355629,1790180476,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nBasic and Clinical Immunology  \nTGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity inEgfr-Mutant Lung Cancer  \nTadahiro Kuribayashi1 | Jun Nishimura1 | Sachi Okawa1 | Masataka Taoka1 | Shunta Mori1 | Takaaki Tanaka1 | Tomoka Nishimura1 | Ayako Morita1 | Naofumi Hara2 | Kiichiro Ninomiya3 | Go Makimoto2 | Kammei Rai4 |  \nEiki Ichihara5  | Katsuyuki Hotta4  | Yosuke Togashi2  | Yoshinobu Maeda1 | Katsuyuki Kiura2 | Kadoaki Ohashi2   \n1Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan | 2Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan | 3Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan | 4Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan | 5Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan  \nCorrespondence: Kadoaki Ohashi ([pbto124g@s.okayama-u.ac.jp](pbto124g@s.okayama-u.ac.jp))  \nReceived: 1 September 2025 | Revised: 6 February 2026 | Accepted: 16 February 2026  \nKeywords: EGFR | lung cancer | nintedanib | osimertinib | TGF-β  \nABSTRACT  \nImmunotherapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) remains challenging. We previously found that EGFR-tyrosine kinase inhibitors induced antitumor immunity but also triggered immunosuppressive cytokines, including transforming growth factor-β (TGF-β), in Egfr-mutant lung cancer. Here, we investigate whether TGF-β inhibition potentiates osimertinib-induced antitumor immunity using a syngeneic mouse model ofEgfr-mutated lung cancer, with cancer cells subcutaneously transplanted into wild-type C57BL/6J mice. We evaluated the antitumor effect of the combination therapy with osimertinib and either nintedanib (an indirect TGF-β inhibitor) or vactosertib (a specific TGF-β type I receptor kinase inhibitor). Changes in the tumor microenvironment during treatment were assessed using immunohistochemical staining, western blot analysis, and flow cytometry. We found that TGF-β expression was upregulated in the tumor treated with osimertinib. Nintedanibmonotherapy showed no significant antitumor effect, whereas osimertinib combined with nintedanib significantly potentiatesthe antitumor effect compared with osimertinib monotherapy in vivo. Crucially, no additive effect of nintedanib on osimertinib monotherapy was observed in vitro. Combination therapy with osimertinib and nintedanib significantly increased effector T cells (CD8+CD44+CD62L−) and Granzyme B+ areas and decreased CD206+ cells, while significantly decreasing TGF-β and SMAD2/3 expression. Similar effects were observed with vactosertib but not with a vascular endothelial growth factor receptor 2 inhibitor. In conclusion, combination therapy with osimertinib and TGF-β inhibitors potentiates osimertinib-induced antitumor immunity. These findings highlight a novel therapeutic strategy for EGFR-mutated NSCLC and warrant further clinical investigation.  \n1 | Introduction  \nLung cancer is the leading cause of cancer-related incidence and mortality worldwide [1]. Epidermal growth factor receptor (EGFR) mutations are frequently observed in non-smokers and East-Asian  \npopulations, accounting for approximately 50% of lung adenocarcinomas [2]. With the rising incidence of never-smoking lung cancer [3], the relevance of EGFR-mutant lung cancer is growing. Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), is one of the standard treatments for EGFR-mutant  \n\n| Abbreviations: EGFR, epidermal growth factor receptor; FCM, flow cytometry; FGFR, fibroblast growth factor receptor; ICI, immune checkpoint inhibitor; IHC, immunohistochemistry; MDSC, myeloid-derived suppressor cell; NSCLC, non-small-cell lung cancer; PDGFR, platelet-derived growth factor receptor; TGF-β, transforming growth factor-β","cbCaihFPIDuR39S2","https://ap.wps.com/l/cbCaihFPIDuR39S2","pdf",12266025,13,"English","# Introduction\n## Immunotherapy challenges in EGFR-mutant NSCLC\n## Rationale for TGF-β inhibition with EGFR-TKI","[{\"question\":\"Why is immunotherapy challenging in EGFR-mutated NSCLC?\",\"answer\":\"Clinical trials show limited efficacy of immune checkpoint inhibitors in EGFR-mutant NSCLCs, likely due to low immunogenicity and an immunosuppressive tumor microenvironment driven by oncogenic EGFR signaling.\"},{\"question\":\"What did the study test to potentiate osimertinib-induced immunity?\",\"answer\":\"The study evaluated whether TGF-β inhibition potentiates osimertinib-induced antitumor immunity by combining osimertinib with nintedanib or vactosertib and assessing changes in the tumor microenvironment.\"},{\"question\":\"What immune and molecular changes were observed with the combination therapy?\",\"answer\":\"Combination therapy increased effector T cells (CD8+CD44+CD62L−) and Granzyme B+ areas while decreasing CD206+ cells, along with reduced TGF-β and SMAD2/3 expression.\"}]","TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer | PDF",1790120209,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d4651d2a21a29a6dd88270c7d468217.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9851af31f472886a057ec0b5afaf1f28.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee317b01d0e0937a94fbb00614c29fc9.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b96bdaa96a09200d3fcedac5c613e416.webp",980,1287]